赛诺菲与韩国SK Chemical合作开发肺炎球菌疫苗

关键词： 赛诺菲 SK Chemical 肺炎球菌疫苗

                               
登录/注册后可看大图

2014年3月20日讯 /生物谷BIOON/ --赛诺菲（Sanofi）3月19日宣布，旗下疫苗事业部赛诺菲巴斯德（Sanofi Pasteur）已与韩国SK Chemical公司达成长期战略合作协议，共同开发创新的肺炎球菌结合疫苗（PCV）。该项合作，将使赛诺菲进入价值40亿美元的全球PCV市场。目前，世界卫生组织（WHO）建议所有国家使用肺炎球菌结合疫苗。

该项合作协议包括，研发、生产和商业化一种预防性肺炎球菌病疫苗。作为协议的一部分，赛诺菲将支付2300万美元的预付款，双方将共同投资开发PCV疫苗项目。如果成功，SK Chemical将在其位于韩国南部的生产基地生产这种创新的疫苗，产品一经注册，将由赛诺菲在全球上市，SK Chemical拥有疫苗在韩国的独家商业化权利。

根据世界卫生组织（WHO），由肺炎链球菌导致的疾病，如肺炎、脑膜炎和菌血症发热，已构成了严重的全球公共健康问题；中耳炎、鼻窦炎、支气管炎也较常见，但感染表现不太严重。据估计，每年约有1450万例严重肺炎球菌疾病发生，在1-59个月儿童群体中每年导致82.6万例死亡。（生物谷Bioon.com）

英文原文：Sanofi teams up with South Korean group on pneumococcal vaccine

Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY), announced today a long-term strategic cooperation with SK Chemical Co. to co-develop an innovative pneumococcal conjugate vaccine (PCV). This agreement will enable Sanofi Pasteur to access the global PCV market of $4 billion USD. The World Health Organization (WHO) recommends the use of PCVs in all countries.

The collaboration agreement includes research & development, production, and commercialization of a preventative pneumococcal disease vaccine. As part of the agreement, Sanofi will make an up-front payment of $23 million USD to SK Chemical Co. Both companies will co-invest in the development of the PCV vaccine project and, if successful, SK Chemical would produce the innovative vaccine at its production facility located in An-dong–the southern part of Korea. The product, once registered, would be launched globally by Sanofi Pasteur with shared profits outside of Korea, where SK would commercialize it with exclusive rights.

“Sanofi Pasteur is committed to driving the open innovation strategy in improving global public-health concerns, and to this end, this collaboration with SK Chemical will showcase a win-win partnership built on mutual strengths and expertise of each company;” said Sanofi Pasteur CEO, Olivier Charmeil. “With this agreement, Sanofi Pasteur will enlarge its unique portfolio of products, embracing the value of open innovation.”

“This is an important milestone for SK and for Korea,” stated Mr. In-Serk Lee, CEO of SK Chemical “We are proud to partner with Sanofi Pasteur, one of the global leaders of the vaccine industry, to be able to develop and manufacture in Korea a premium vaccine that has the potential to be distributed worldwide.”

According to the WHO, diseases caused by Streptococcus pneumoniae (pneumococcus)–such as pneumonia, meningitis and febrile bacteraemia–constitute a major, global public-health problem; otitis media, sinusitis and bronchitis are more common but less serious manifestations of infection. It is estimated that about 14.5 million episodes of serious pneumococcal disease occur annually, resulting in about 826,000 deaths in children aged 1-59 months.

SK Chemical recently unveiled its state-of-the-art, quality by design, multi-product production facility. The plant is currently producing various vaccines for clinical trials. Once the testing is over, the plant will start producing vaccines at large scale using next-generation technologies.

(责任编辑：lishuheng)